Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Cognitive Effects of VU319 in Healthy Volunteers
NCT03220295Phase 1Completed
- Sponsor
- Vanderbilt University
- Start
- Jul 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VU0467319 in Alzheimer's disease (AD) (9 arms), sponsored by Vanderbilt University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jul 2017; status: completed.
02
Drugs
VU0467319
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03220295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220295.